Key result
Mivacurium resulted in significantly longer corrected QT dispersion at 15 minutes compared to atracurium and was associated with a higher incidence of pathological QTc prolongation.
Why the study?
The study aimed to investigate the effects of rocuronium, mivacurium, and atracurium on arrhythmia markers, QT interval, and QT dispersion under general anesthesia.
Does the choice of muscle relaxant (rocuronium, mivacurium, or atracurium) affect QT interval and QT dispersion in patients undergoing general anesthesia?
RCT (n=90)
Observer-blind
Closed envelop method
No
Does the choice of muscle relaxant (rocuronium, mivacurium, or atracurium) affect QT interval and QT dispersion in patients undergoing general anesthesia?
p-value: p=<0.05
Mivacurium may be associated with a higher risk of pathological QTc prolongation compared to rocuronium and atracurium during general anesthesia, suggesting caution in patients with long QT syndrome.
May warrant QT caution with mivacurium; leaves open optimal relaxant choice in arrhythmia-prone patients.
Objective: The aim of the study was to investigate the effects of rocuronium, mivacurium, and atracurium on arrhythmia markers, QT interval, and QT dispersion (QTd). Method: Ninety patients scheduled for septorhinoplasty were randomly assigned to one of three groups of 30. During the induction of anesthesia, muscle relaxants of 0.6 mg/kg rocuronium in Group R, 0.2 mg/kg mivacurium in Group M, and 0.5 mg/kg atracurium in Group A were employed. Mean blood pressure (MAP), heart rate (HR), and electrocardiogram (ECG) values were measured before induction of anesthesia (T0), immediately after induction of anesthesia (T1), at 1 minute (T2), 5 minutes (T3), 10 minutes (T4) and 15 minutes (T5) after muscle relaxant administration, and QT, corrected QT (QTc), QTd and corrected QTd (QTcd) intervals were recorded. Results: When the groups were compared in terms of QTcd values, the difference between mivacurium and atracurium was significant in terms of T5 values, and atracurium (T5) QTcd was found to be shorter (p<0.05). Group M had 5 of the 6 measures with pathological QTc prolongation. Conclusions: Because the prevalence of pathological QTc is greater in mivacurium, further clinical trials should be conducted to challenge the use of mivacurium in individuals with a long QT interval.
No takes yet. Share an insight, caveat, or question.
KURT et al. (2022) conducted an RCT in Patients undergoing septorhinoplasty under general anesthesia (n=90). Mivacurium vs. Atracurium and Rocuronium was evaluated on Corrected QT dispersion (QTcd) at 15 minutes (p=<0.05). Mivacurium resulted in significantly longer corrected QT dispersion at 15 minutes compared to atracurium and was associated with a higher incidence of pathological QTc prolongation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: